Microdosing, neuropsychedelia, and psilocybin therapy are just some of the topics that will be discussed at a free one-day workshop and webinar at UC Davis Health in Sacramento on March 23rd.
The Psychedelic Summit will bring together national experts to explore what the rapidly evolving field of psychedelics and neurotherapy could mean for neuropsychiatric and neurodegenerative diseases. These new treatments may hold promise for anxiety, depression, substance abuse, obsessive-compulsive disorder, and post-traumatic stress disorder, among others.
The event will be presented by David Lubarsky, Vice Chancellor of Human Health Sciences and CEO of UC Davis Health. The Psychedelic Summit is hosted by the UC Davis Department of Psychiatry and Behavioral Sciences, the Psychedelic and Neurotherapy Institute, and the Center of Excellence in Behavioral Health.
David E. Olson, University of California, Davis
Psychedelics and plasticity-promoting neurotherapy
Mark Geyer, University of California, San Diego
Neuropsychedelia: from psychotomimetics to psychotherapy
Joshua Wooley, University of California, San Francisco
Psilocybin Therapy Research: Current Issues and Future Perspectives
Harriet De Wit, University of Chicago
Microdosing: fact or fiction?
Frederick Streeter Barrett, Johns Hopkins University
Neuropsychological mechanisms of action of classical psychedelic drugs
Dakshin Ramanathan, University of California, San Diego
Beyond Psychedelics: Enhancing Mood-Enhancing Effects with Plasticity-Based Personalized Interventions
Conor Liston, Weill Cornell Medicine
Research and rescue of dysfunctional brain circuits in depression
The Psychedelic Summit will take place at the MIND Institute Auditorium on March 23 from 9:00 AM to 5:00 PM PDT. A limited number of seats are available in person. For personal participation, register here. For a virtual visit, register here.